Literature DB >> 3128452

Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.

E Berntorp1, I M Nilsson.   

Abstract

The following commercial virus-inactivated factor VIII concentrates were studied in vitro: AHF-Kabi and Octonativ, KabiVitrum; Hemofil T, Hyland; Factorate HP and Monoclate, Armour; Nordiocto, Nordisk Gentofte (dry heated); Kryobulin TIM3, Immuno (steam treated); Profilate, Alpha (heated as dry material slammed in heptane); Hemate P, Behring (wet heated) and Octa-V.I., Octapharma (solvent/detergent treated). The concentration of VIII:C was lowest in AHF-Kabi, whereas it ranged from 24 to 53 IU/ml in the high purity concentrates, except for Monoclate in which it ranged from 91-128 IU/ml. All concentrates but Octa-V.I. had higher values for VIII:Ag than for VIII:C. von Willebrand factor with normal distribution of multimers could only be demonstrated in AHF-Kabi and Hemate P. In vivo studies were performed in 12 severe hemophiliacs. Recovery and half-life of VIII:C did not differ between the various concentrates. Hemate P was given to 5 patients with severe von Willebrand's disease, in all of whom a correction of the hemostatic defect was seen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128452     DOI: 10.1111/j.1600-0609.1988.tb00825.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

2.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.